The educational project connected to LabEx is at Master and PhD levels and the creation of a training program ranging from Level IV to Level I is also proposed.
Master and PhD level training
The LabEx is already engaged in three Master level courses which form part of the training offered at: Université François-Rabelais of Tours and the Montpellier University.
- In 2011, at the start of the academic year, the University of Tours created a third round of M2 course in therapeutic antibodies, in addition to the course “Cellular and Molecular Infectious Diseases – ICM”, “Infectious Immunology and Vaccinology – IIV” within the Specialty ICMV (M1 and M2). This will become ICMVAT (Cellular and Molecular Infectious Diseases, Vaccinology and Therapeutic Antibodies) in the framework of the future four-year contract (2012-2015). After the first year of common teaching (M1), students can choose from three themed courses, including “Immuno-Pharmacology and Therapeutic Antibodies” (IAT).
- The current “Biology, Health and Alimentation” Master level includes the professional orientated specialty “Biotechnology and Law”, whose characteristic is to approach two M1 student populations, lawyers and scientists. They will acquire supplementary knowledge to enable them to prepare patent applications or manage the regulatory aspects of biotechnology activity. This will facilitate employment at the interfaces between consulting firms, biotechnology companies and academic institutions etc.
- The University of Montpellier proposes a Masters in “Project Management and Innovation in Biotechnology” (BIOTIN). This is a two year M1 and M2 Masters level course. In order to simplify access and optimize educational effectiveness, it unites all the training provided in the Languedoc-Roussillon region in the field of biotechnology for health and all the higher education institutions (universities and engineering schools) involved in this sector. Among the units of study proposed in the BIOTIN Masters, those entitled “Immunotechnologies”, “Engineering of Biomolecules” and “Bioinformatics and Biostatistics applied to biology” proposed in M1, as well as the unit of study “Bioinformatics of antibodies – immunoinformatics” proposed in M2 are in perfect harmony with the LabEx theme.
The medium-term perspective will consider the creation of a specialty entitled “Therapeutic Antibodies”. In order to have sufficient students (pharmacists, physicians, and scientists), the specialty “Therapeutic Antibodies” would be national and there would be joint collaboration between the Universities of Montpellier and Tours.
This specialisation, which does not yet exist at a national level, seems essential considering the growing importance of monoclonal antibodies in numerous therapeutic fields. Offered as an M2 second year level course, it will be dedicated to theoretical and practical learning. A major effort will be made to facilitate student contact with the hospital and industrial systems in both regions, in order to promote direct exchanges with the players in each field and to enable the selection of relevant courses.
The objectives of this training course are to cover research and development aspects, engineering and the pharmacology of antibodies, and perhaps even legal aspects.
Creation of a training program ranging from Level IV to Level I
In addition to training at masters and then doctoral level the creation of a complete chain of vocational-type training is expected. Moreover, since 1998 a convention has existed between the Université François-Rabelais and the Groupe IMT (Expert training institute for the pharmaceutical, cosmetic and biotechnology industries).
This convention has among other things, created an authentic training program ranging from technician level (Level IV) to Masters level (Level I) in the pharmaceutical and cosmetic industries. Teacher exchanges and availability of the IMT technical plateau unique in France enable the training and/or provision of semi-industrial or industrial equipment for research and development in “galenic chemicals” for doctoral students.
Similarly for biotechnology training courses, LabEx participates in the creation of Level IV to Level I training courses, using IMT know-how to build a training program similar to existing “galenic chemical” productions in the pharmaceutical industry. Training courses for technicians, senior technicians, specialized technicians, professional Bachelor’s degree and Masters in industrial pharmaceutical-biotechnology and engineering and quality control careers are to be developed with input from the IMT.
This training project has led the PRES (Regional higher education center) Centre Val de Loire Université, now called COMUE Leonard de Vinci, to the creation, as part of “Investments for the Future” and in the call for projects “invest in professional training programs” of the first French Institute of biodrugs and cosmetics BIO3 Institute.
The Bio3 Institute will accordingly meet both main objectives of this program: to update and extend professional training programs by the development of an innovative technical plateau in France and to develop housing solutions tailored to the needs of young people who are committed to professional training programs.
The Bio3 Institute is in line with the COMUE in order to reinforce the MAbImprove Laboratoire d’ Excellence training dimension.